Detailed Information

Cited 15 time in webofscience Cited 15 time in scopus
Metadata Downloads

Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea

Authors
Lee, Min JinChang, Sung WonKim, Ji HoonLee, Young-SunCho, Sung BumSeo, Yeon SeokYim, Hyung JoonHwang, Sang YounLee, Hyun WoongChang, YoungJang, Jae Young
Issue Date
Feb-2021
Publisher
SPRINGER
Keywords
Hepatocellular carcinoma; Real-world study; Effectiveness; Safety
Citation
Investigational New Drugs, v.39, no.1, pp.260 - 268
Indexed
SCIE
SCOPUS
Journal Title
Investigational New Drugs
Volume
39
Number
1
Start Page
260
End Page
268
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/33931
DOI
10.1007/s10637-020-00977-4
ISSN
0167-6997
Abstract
Background/Aims Regorafenib has been approved as a second-line systemic therapy for hepatocellular carcinoma (HCC) patients after the phase III RESORCE trial. This study analyzed real-world data to assess the clinical effectiveness and safety of regorafenib compared to the RESORCE trial. Methods This multicenter cohort study included HCC patients treated with regorafenib after sorafenib (n = 133). We evaluated the time to progression (TTP), progression-free survival (PFS), overall survival (OS), and safety in patients receiving regorafenib along with the predictors of prognosis. Results The median age was 60 years and 81.2% patients were men. Hepatitis B virus infection (68.4%) was the commonest etiology. Most patients were classified as Child-Pugh A (98.5%) and had extrahepatic metastasis (84%) and vascular invasion (45.1%). This study demonstrated similar characteristics apart from more frequent hepatitis B etiology and more vascular or extrahepatic involvement compared with the RESORCE trial. An objective response rate of 12.5% was obtained for response assessment (n = 112); the disease control rate was 34.8%. Thirty-eight patients died during follow-up. With regorafenib, the median OS, PFS, and TTP were 10.0, 2.7, and 2.6 months, respectively. In the exploratory analysis after sorafenib administration, the median OS was 25.8 months. The rate of response and survival were comparable to those in the RESORCE trial. Child-Pugh score > 5, alpha-fetoprotein > 400 ng/ml, and TTP for sorafenib ≥ median were independently associated with OS. Conclusions This real-word regorafenib study showed comparable effectiveness and safety to the RESORCE trial. Regorafenib improves the prognosis of patients with prolonged TTP during previous sorafenib therapy.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Ji Hoon photo

Kim, Ji Hoon
구로병원 (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE